

Supplementary Table 2. Exposure metrics of ADC and MMAE following intravenous administration of brentuximab vedotin 1.8 mg/kg Q3W at steady state by age subgroup (PK subpopulation).

Parameter	Age (years)	ADC geometric mean (%CV)	Parameter	Age (years)	MMAE geometric mean (%CV)
C_{max} ($\mu\text{g/mL}$)	<6 (n=3)	22.5 (4.42)	C_{max} (ng/mL)	<6 (n=3)	0.95 (16.9)
	6–12 (n=21)	29.5 (13.09)		6–12 (n=20)	1.17 (50.8)
AUC_{0-21d} ($\mu\text{g}\cdot\text{day/mL}$)	<6 (n=3)	53.08 (16.2)	AUC_{0-21d} (ng $\cdot\text{day/mL}$)	<6 (n=3)	5.5 (20.8)
	6–12 (n=21)	79.82 (26.3)		6–12 (n=20)	8.97 (53.1)
C_{ave} ($\mu\text{g/mL}$)	<6 (n=3)	2.53 (16.2)	C_{ave} (ng/mL)	<6 (n=3)	0.26 (20.84)
	6–12 (n=21)	3.8 (26.3)		6–12 (n=20)	0.43 (53.07)
CL (L/day)	<6 (n=3)	0.55 (14.84)	CL_m (L/day)	<6 (n=3)	23.92 (1.66)
	6–12 (n=21)	0.95 (26.46)		6–12 (n=20)	37.07 (24.37)
Weight-adjusted CL (L/day)	<6 (n=3)	1.44 (15.4)	Weight-adjusted CL_m (L/day)	<6 (n=3)	61.9 (3.83)
	6–12 (n=21)	1.36 (19.0)		6–12 (n=20)	53.3 (13.1)

%CV, percentage coefficient of variation; ADC, antibody-drug conjugate; AUC_{0-21d} , area under the concentration versus time curve from time 0 to 21 days postinfusion; C_{ave} , average observed concentration; C_{max} , maximum observed concentration; CL, clearance; CL_m , metabolic clearance; MMAE, monomethyl auristatin E; PK, pharmacokinetic; Q3W, every 3 weeks.